TIC Solutions, Inc. TIC 深 沪
已收盘 02-06 16:00:00 美东时间
9.55
+0.550
+6.11%
华盛通- 最 高9.63
- 今 开9.13
- 成交量 338.26万股
- 最 低 8.92
- 昨 收 9.00
- 总市值 21.13亿
- 52周最高 14.9442
- 市盈率 静 --
- 换手率 1.53%
- 52周最低 8.755
- 委 比 -36.36%
- 总股本 2.21亿
- 历史最高 14.9442
- 量 比 1.31
- 振 幅 7.89%
- 历史最低 8.755
- 每 手 1
- 风险率 1.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
JP Morgan Initiates Coverage On TIC Solutions with Overweight Rating, Announces Price Target of $16
JP Morgan analyst Tomohiko Sano initiates coverage on TIC Solutions (NYSE:TIC) with a Overweight rating and announces Price Target of $16.
01-09 20:35
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
TIC Solutions shares are trading higher after the company reported better-than-expected Q3 sales results and issued FY25 sales guidance above estimates.
TIC Solutions shares are trading higher after the company reported better-than-...
2025-11-12 21:42
TIC Solutions Affirms FY2025 Sales Guidance of $1.530B-$1.565B vs $1.139B Est
TIC Solutions (NYSE:TIC) affirms FY2025 sales outlook from $1.530 billion-$1.565 billion to $1.530 billion-$1.565 billion vs $1.139 billion estimate.
2025-11-12 21:10
Acuren Q3 EPS $(0.08) Misses $0.04 Estimate, Sales $473.888M Beat $469.174M Estimate
Acuren (NYSE:TIC) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $0.04 by 316.22 percent. The company reported quarterly sales of $473.888 million which beat the analyst
2025-11-12 20:05
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
2025-10-13 11:26
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
2025-10-10 11:36
UBS Maintains Neutral on Acuren, Raises Price Target to $15
UBS analyst Joshua Chan maintains Acuren (NYSE:TIC) with a Neutral and raises the price target from $11 to $15.
2025-10-10 01:37
